A Phase 1 interventional study of PRT-064040 nasal spray and Placebo in Migraine, sponsored by Sichuan Purity Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Sichuan Purity Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Migraine Disorders with a site in China — 34 open to participants now, 40 under way, 10 of them phase 3. Migraine Disorders · China.
Among the 80 studies in Migraine Disorders with a site in China, this one is the 50th largest by enrollment of the 61 interventional ones that give a count, is one of 13 that started in 2025, is one of 3 in phase 1, and was the 65th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →34 of the 80 studies in Migraine Disorders with a site in China are open now. Recruiting first, the newest first:
Brise Pharmaceuticals Co., Ltd. · Sites in China
Ages 18+
Pfizer · Sites in China, United States, Israel and 1 more country
Ages 18+
Pfizer · Sites in China, United States, Israel
Ages 18+
Sichuan Purity Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18–75
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 25 · Phase 4 7
First in 2007; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is close to the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 288 across the 61 interventional studies, 330 across the 19 observational. Of the 29 that completed or were terminated, 10 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 80 have an industry lead sponsor. The 10 most frequent:
Sichuan Purity Pharmaceutical Technology Co., Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Sichuan Purity Pharmaceutical Technology Co., Ltd. has 2 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
9 of the studies in Migraine Disorders with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07347028Beijing Tiantan HospitalClinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Knee Osteoarthritis(OA) | 2026-12-01 |
| NCT07347067Beijing Tiantan HospitalClinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine | 2026-12-01 |
| NCT06347276China National Center for Cardiovascular DiseasesCerebral Microembolization Associated With PFO Closure | 2026-12-31 |
| NCT06953622Peking University Third HospitalEstablishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 80 studies in Migraine Disorders with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is a Phase I, single-center, randomized, double-blind, placebo-controlled study conducted in healthy Chinese adult subjects.
The purpose of this study is to learn about:
This study is divided into two parts:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PRT-064040 nasal spray
Drug: Placebo
Drug: PRT-064040 nasal spray
Drug: Placebo
A single dose of PRT-064040 nasal spray at one of six dose levels
A single dose of Placebo at one of six dose levels
Multiple doses of PRT-064040 nasal spray at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days
Multiple doses of Placebo at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days
The incidence and severity of adverse events
Time frame: From first dose to maximum of 2 days post last dose administration
Pharmacokinetic Parameters: Cmax
Time frame: Up to 2 days post last dose administration
Pharmacokinetic Parameters: Tmax
Time frame: Up to 2 days post last dose administration
Pharmacokinetic Parameters: AUC
Time frame: Up to 2 days post last dose administration
Pharmacokinetic Parameters: Half life
Time frame: Up to 2 days post last dose administration
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Sep 2025, 3 months.
Of 39 industry-sponsored phase 1 interventional studies under Migraine Disorders, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 3 months is below that.
Counting every sponsor, half of 53 studies reached it within 6 months; a quarter within 2 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sichuan Purity Pharmaceutical Technology Co., Ltd.